S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIA non‑small‑cell lung cancer

  • Authors:
    • Katsuhiro Okuda
    • Motoki Yano
    • Tsutomu Tatematsu
    • Katsumi Nakamae
    • Takeshi Yamada
    • Toshio Kasugai
    • Tsutomu Nishida
    • Masaaki Sano
    • Satoru Moriyama
    • Hiroshi Haneda
    • Osamu Kawano
    • Ryoichi Nakanishi
  • View Affiliations

  • Published online on: November 2, 2017     https://doi.org/10.3892/mco.2017.1481
  • Pages:73-79
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

The majority of patients with completely resected stage II or IIIA non‑small‑cell lung cancer (NSCLC) require adjuvant chemotherapy to improve survival following surgery. In the present trial, the 2‑year disease‑free survival (DFS), and the feasibility and safety of S‑1 as an adjuvant chemotherapy for advanced lung cancer were evaluated. A total of 40 patients with completely resected stage II or IIIA NSCLC were enrolled and randomized to receive postoperative chemotherapy with either up to 4 cycles of paclitaxel plus carboplatin (arm A) or with up to 1 year of S‑1 (arm B). The primary endpoint was 2‑year DFS. The secondary endpoints were feasibility and toxicity. A total of 40 patients were enrolled, but 3 were excluded in accordance with the exclusion criteria. The remaining 37 patients were analyzed. The 2‑year DFS rate was 54.2% in arm A and 84.2% in arm B. Overall, 15/18 (83.3%) patients completed 4 cycles of paclitaxel plus carboplatin and 13/19 (68.4%) completed 1‑year of S‑1adjuvant chemotherapy. Of the 18 (16.7%) patients in arm A, 3 experienced grade 3 or 4 adverse events, while none in arm B experienced such events. Therefore, S‑1 chemotherapy for patients with completely resected stage II or IIIA NSCLC was a feasible and safe regimen, and it may therefore be considered as a potential adjuvant chemotherapy option for advanced NSCLC.

Related Articles

Journal Cover

January 2018
Volume 8 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Okuda, K., Yano, M., Tatematsu, T., Nakamae, K., Yamada, T., Kasugai, T. ... Nakanishi, R. (2018). S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIA non‑small‑cell lung cancer. Molecular and Clinical Oncology, 8, 73-79. https://doi.org/10.3892/mco.2017.1481
MLA
Okuda, K., Yano, M., Tatematsu, T., Nakamae, K., Yamada, T., Kasugai, T., Nishida, T., Sano, M., Moriyama, S., Haneda, H., Kawano, O., Nakanishi, R."S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIA non‑small‑cell lung cancer". Molecular and Clinical Oncology 8.1 (2018): 73-79.
Chicago
Okuda, K., Yano, M., Tatematsu, T., Nakamae, K., Yamada, T., Kasugai, T., Nishida, T., Sano, M., Moriyama, S., Haneda, H., Kawano, O., Nakanishi, R."S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIA non‑small‑cell lung cancer". Molecular and Clinical Oncology 8, no. 1 (2018): 73-79. https://doi.org/10.3892/mco.2017.1481